Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 2
In part two of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss the link between HSV and NMDAR encephalitis and how that impacts longitudinal recovery. Show reference: ht...
25 Nov 20241min
Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 2
In part two of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss the link between HSV and NMDAR encephalitis and how that impacts longitudinal recovery. Show reference: ht...
25 Nov 20241min
Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 1
In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss long-term cognitive and functional outcomes in patients with anti-NMDAR encephalitis and their implications...
22 Nov 20241min
Myelitis Associated With Rheumatologic Disease - Part 2
In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimm...
21 Nov 20243min
Myelitis Associated With Rheumatologic Disease - Part 1
In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying c...
20 Nov 20244min
Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?
Dr. Tesha Monteith discusses the Brain & Life article, "Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?" by Hallie Levine, available in the latest issue of Brain & Life or at br...
19 Nov 20241min
CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 3
In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS. Show reference: https://www.neurology.org/doi/abs/10.1212...
18 Nov 20242min
The Placebo Effect
Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments.
15 Nov 20241min
